Founded in 2014, HaploX aims to integrate liquid biopsy technology, gene sequencing, artificial intelligence, big data, and other technologies to improve the management of cancer patients.
HaploX’s technologies include tools for capturing circulating tumor DNA; extracting and amplifying ultra-low concentrations of DNA from liquid samples; performing tagged sequencing; and managing and analyzing the resulting data.
Presently, HaploX’s polycentric global distribution include: Shenzhen R & D Headquarter, Third-party Medical Laboratory, GMP Factory, US R & D center and ShangRao International Precision Medical Health Industrial Park. HaploX obtained a certificate of participation from EMQN(The European Molecular Genetics Quality Network) in 2017 and achieved both satisfactory results in two external quality assessment schemes: Lung Cancer(NSCLC)2 and Oncogene panel testing.
HaploX possesses the most advanced platforms in the world: Illumina’s NextSeqs, HiSeq X Tens, NovaSeq 6000 series and digital PCR. HaploX’s throughput is now the second in the world rankings.
In December 28th, 2017, HaploX Biotechnology raised $32 million in series A+ round. At the same time, NIVIDA accepted HaploX as a member in Inception program(a program started by NIVIDA in order to support startups that are revolutionizing industries with advances in artificial Intelligence and data science). The firm will continue to develop its sequencing technology, which is capable of detecting circulating tumor DNA for personalized cancer therapy.
Company Details
- Employees
- 23
- Founded
- -
- Address
- 南山区高新北区松坪山路奥特迅电力大厦8层, 深圳,广东省 518100,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- haplox.com
- Keywords
- Liquid Biopsy, Gene Sequencing, Artificial Intelligence, Precise Medical, Big Genomic Data, Ultramicro-tumor Gene Detection, Tumor Prevention, Tumor Diagnosis, Tumor Prognosis and Monitoring, Personalized Cancer Therapy.
- HQ
- 深圳, 广东省
Haplox Biotechnology Questions
Haplox Biotechnology's website is haplox.com
Haplox Biotechnology's LinkedIn profile is https://cn.linkedin.com/company/haplox-biotechnology
Haplox Biotechnology has
23 employees.
View email and phone details for 23
employees at Haplox Biotechnology.
Haplox Biotechnology's industry is
Biotechnology Research
Haplox Biotechnology's top competitors are
Microsynth Ag,
Genebiohealth Co., Ltd,
Bioxpedia A/s,
Jover&soes,
Haplox Global,
Immunogene Laboratories,
Drgs Lifetech,
Asosiasi Genomik Indonesia (Agi),
Bgi Genomics,
Regeneron.
Haplox Biotechnology's categories are Biotechnology Research
Haplox Biotechnology's founding year is 2014
